Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan

By: Everest Medicines Limited via ACN Newswire

August 08, 2025 at 05:09 AM EDT

HONG KONG, Aug 8, 2025 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R). NEFECON(R) is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression, irrespective of proteinuria levels.

With this label update, the previous requirement in accelerated approval stage to submit full confirmatory trial analysis to demonstrate clinical benefit has been formally removed. Additionally, data demonstrating NEFECON(R)’s efficacy in delaying kidney function decline has been included in the approved product label. IgAN is highly prevalent among Asian populations, with a 56% higher risk of progression to end-stage renal disease compared to other groups and often progresses more rapidly.

Taiwan region became the last region across all Everest’s territories to grant full approval for NEFECON(R), together with Mainland China, Singapore, Macao SAR, Hong Kong SAR and South Korea. This further demonstrates NEFECON(R)’s foundational first-line cornerstone treatment for IgAN patients.

"NEFECON(R) has received full approval in Taiwan, further validating its outstanding clinical value and offering physicians a more solid clinical foundation for treatment decisions.” Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said. “As the first and only fully approved etiological treatment for IgAN, NEFECON(R) has now achieved full approval across Asia. This milestone will benefit a broader patient population by enabling more individuals with IgAN to access this etiological treatment earlier, helping to slow disease progression and improve quality of life. We will continue to expand the accessibility and affordability of NEFECON(R) across Asia, aiming to benefit more IgAN patients and improve their quality of life."

The approval is based on the global Phase 3 NefIgArd clinical trial, which showed that compared to placebo, it not only brought about a durable reduction in proteinuria and reduced the frequency of microscopic hematuria but also demonstrated clinically relevant and statistically significant treatment benefits in estimated glomerular filtration rate (eGFR), reducing the decline in kidney function by 50% over a period of 2 years, comprising 9 months of treatment and 15 months of observation, and potentially delaying the progression to dialysis or kidney transplantation by 12.8 years.

Additionally, the complete 2-year data of the NefIgArd study further analyzed the potential differences in the response to NEFECON(R) treatment between Asians (n=83) and Caucasians (n=275). The results showed that compared to placebo, treatment with NEFECON(R) for 9 months in both Asians and Caucasians can significantly delay the decline of eGFR, protect kidney function, and bring about a sustained reduction in proteinuria and reduce the risk of microscopic hematuria.

NEFECON(R) has been recommended by several authoritative treatment guidelines, including the “KDIGO 2024 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)”, and the "Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)". NEFECON(R) was included in China’s National Reimbursement Drug List (NRDL) in November 2024, and the supplemental application for the production expansion of NEFECON(R) has been officially approved by NMPA in August 2025.

NEFECON(R) is currently the world’s first IgAN treatment to have received full approval from the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency（MHRA）in the United Kingdom , as well as in other Asian territories where Everest Medicines holds the rights, including Hong Kong SAR, Macao SAR, Taiwan region (China), Singapore, and South Korea.

About Us

About Cabling Installation & Maintenance

Contact Cabling Installation & Maintenance

Editorial

Advertising and Sponsorship Sales

Subscriptions and Memberships

Feedback/Problems

Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan

More News